Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 7/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3715122 | 0.99 | TRPM8 (0.51) | TRPM8HTR2CHDAC3HDAC4HDAC1 | |
| SCHEMBL1115277 | 0.84 | TRPM8 (0.53) | TRPM8ATMSIGMAR1KDM4ECYP19A1 | |
| SCHEMBL538019 | 0.83 | TRPM8 (0.51) | TRPM8HTR2CHDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL3721783 | 0.82 | TRPM8 (0.50) | TRPM8HDAC3HDAC4HDAC1HDAC7 | |
| Hydrochloric Acid SCHEMBL1690752 | 0.82 | TRPM8 (0.50) | TRPM8HTR2CHDAC3HDAC4HDAC1 | |
| SCHEMBL13188809 | 0.81 | TRPM8 (0.58) | TRPM8SIGMAR1 | |
| SCHEMBL28499917 | 0.80 | HTR2C (0.50) | TRPM8HTR2CHTR6 | |
| SCHEMBL12481896 | 0.80 | CHRNA7 (0.41) | TRPM8HTR2CHDAC3HDAC4HDAC1 | |
| SCHEMBL28507645 | 0.77 | HTR2C (0.47) | TRPM8HTR2CHDAC3HDAC4HDAC1 | |
| SCHEMBL655154 | 0.76 | ATM (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-20 | — | — | US | disclosed |
| EP-2675812-B1 | CHROMAN - SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2675812-A1 | CHROMAN - SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-09-27 | — | — | US | disclosed |
| WO-2012112743-A1 | CHROMAN - SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ1, KCNC1 | TRPM8 23/4885HTR2C 467/4885HDAC3 170/4885 |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ1, KCNC1 | TRPM8 23/4885HTR2C 467/4885HDAC3 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.